Dear Miss Manners: I am wondering if it would be crass or in poor taste to give a new widow a thoughtful sympathy card with ...

Everton fan and broadcaster David Downie spoke to BBC Radio Merseyside about Dominic Calvert-Lewin's departure: "Right now we ...

Aubrey O’Day has shared her reaction to the results of Sean “Diddy” Combs ‘ trial, which concluded Wednesday (July 2) with a ...

5 Live listeners have their say with Nicky Campbell.

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

A group of faith leaders, community advocates, and activists continues to call on the Monroe County District Attorney’s ...

ICE raids are disrupting worksites across the country, particularly construction sites, as President Trump’s mass deportation ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...